Mixed Urinary Incontinence - An Opportunity for Novel Drug Therapies

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-04-14

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Mixed Urinary Incontinence (MUI) affects over 10% of women, with women suffering from unpleasant symptoms of both urge urinary incontinence (UUI) and stress urinary incontinence (SUI). At present, no pharmacological agent is able to effectively treat the symptoms of both UUI and SUI.


Scope

  • Quantitative treatment data from 288 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments
  • Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and first- to third-line treatments for MUI
  • Influences on treatment choice and perception of current drug therapies including darifenacin, solifenacin and duloxetine
  • Evaluation of unmet needs and future outlook including awareness of R&D drug pipeline


    • Report Highlights
    Approximately only half of women with MUI seek treatment for their condition. Of these women, less than half receive an accurate diagnosis on first presentation to a physician. Drug manufacturers are therefore failing to maximize revenues. A need for better education of both patients and physicians exists.

    With approximately a third of patients most distressed by their SUI symptoms, opportunities still exist for manufacturers with a pharmacological treatment for SUI to establish themselves as physicians' first-line treatment option for MUI.

    Drug treatment rates are higher in MUI overall than in other urinary incontinence disorders, which may favor this market for novel product launches.


    Reasons to Purchase

  • Forecast product sales by understanding key aspects of MUI epidemiology, diagnosis and treatment
  • Gain a better understanding of the challenges facing current and future players in the MUI market
  • Identify physicians key concerns in MUI including unmet needs and the attributes that physicians believe are desirable for future treatments

    • Table of Contents

    Other users found this report page using the following search terms: incontinence overactive bladder urge incontinence stress incontinence incontinence mixed urinary drug mui epidemiology sui novel opp drugs

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.